BioRestorative Therapies' Q3 revenue drops, net loss widens

Biorestorative Therapies

12/11/2025 21:33

Overview

BioRestorative Q3 2025 revenue declines significantly compared to Q3 2024

Company reports Q3 net loss of $3 mln, up from $1 mln in Q3 2024

BioRestorative strengthens financial position with recent stock offering and private placement

Outlook

Company focuses on near-term revenue strategy in BioCosmeceutical platform

BioRestorative aims to expand BioCosmeceutical offerings for FDA approvals

Result Drivers

REVENUE DECLINE - Co attributes significant Q3 revenue decline to timing of BioCosmeceutical orders

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$3 mln
Q3 Operating Income
-$3.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BioRestorative Therapies Inc is $8.00, about 82.4% above its November 11 closing price of $1.41

Press Release: ID:nGNX2CD5j0

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)